XXVI Congress

143 days

19 hours

56 mins

SETGyC 9th biennal congress report - 2

SETGyC 9th biennal congress report - 2

15 May '2018 by Carles Calatayud Aristoy

The focus of my current research is on modeling Parkinson´s disease (PD) by using patient specific induced pluripotent stem cells (iPSC). I started working on this topic in 2013, when I started my PhD in the group of A. Consiglio at the Institute of Biomedicine of the University of Barcelona. Since then, I have been exploring the relationship between PD pathogenic mutations and the genetic makeup of patients. The work I presented in Mallorca, during the 9th edition of the SETGyC Congress, concerned developing a genetic reporter for tracking and/or sorting live dopaminergic neurons derived from iPSC. Specifically, we knocked-in a gene encoding for a fluorescent protein after the last exon of the tyrosine hydroxylase (TH) gene using CRISPR/Cas9 technology (see the figure below for a graphic summary). For several reasons, this reporter line has been long awaited in the field of PD modelling using iPSC. The most important reason is to enable live analysis in a defined cell type among the differentiated progeny. Thanks to this tool, we have been able to study disease-related phenotypes in live cells. After giving my talk, I immediately had a feeling that the work was well received and I received interesting and useful feedback from relevant researchers in the field such as Ernest Arenas (Karolinska Institute, Stockholm) and Juanjo Toledo (IBIS, Sevilla).

The scientific level at the meeting was very high. I was able to attend amazing talks, some topics were very close to my field, some others not so much. The speakers, however, always gave very clear talks with an excellent structure. This made it easy for the audience to follow talks outside their immediate expertise and learn from other fields. The congress had an excellent atmosphere. It was a great opportunity to meet up with colleagues I met before and to get to know new people. Another aspect that I want to highlight is the presence of company representatives, who introduced us to their commercial vision. The industrial application of our findings is something that we sometimes forget about in an academic lab. However, it is encouraging to discover that biotech companies are very active in our field. In this regard, I was particularly interested in the services provided by the company Neuroproof (Rostock, Germany). Their project manager, Benjamin Bader, explained how Neuroproof performs preclinical testing of drug candidates for neurodegenerative disorders using iPSC-derived neurons and their electrophysiological activity as a readout.

On the last day I received the very exciting news that I was one of the winners of the SETGyC Young Investigator Awards, sponsored by ESGCT. I would like to thank the organisers for giving me the prize, which is a confidence boost and a reward for hard work. I look forward to participating in the next edition of the SETGyC Congress, particularly as this will be a joint Congress with ESGCT.

Carles Calatayud Aristoy

Carles Calatayud received his degree in Biotechnology (2011) from the Polytechnic University of Valencia. During his last year of the degree, he worked in the Experimental Hepatology Unit at the Health Research Institute La Fe, Valencia, where, he investigated the effect of two hepatoendoderm-determining transcription factors in the somatic cell reprogramming to pluripotency. He joined the laboratory of Antonella Consiglio at the University of Barcelona in 2012 as a Master student in Biomedical Research. During his thesis he studied the genetic contribution of both the LRRK2 mutation and the genomic environment to the Parkinson’s disease pathogenesis. Nowadays, he is still working as a PostDoc trying to find genetic protection against LRRK2-related neurodegeneration.


The ESGCT blog is written by our members. If you would like to contribute to the blog, please email us. Opinions expressed in the blog are those of the individual and do not necessarily reflect ESGCT’s position...